Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edesa Biotech, Inc.SBOT · Entity 7223 | EVP, Corporate Development | March 12, 2018 | March 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edesa Biotech, Inc.
Report date March 12, 2018 · Filed March 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2025-03-12 | Direct | 30,000 |
Reported balance
After 2018-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-12 · Grant · Acquired 30,000 · Balance 30,000 F1: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2018 Filed Mar 15, 2018 00:19 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | GrantShare Option (Right To Buy) · Derivative | 30,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001144204-18-014749 · tv488518_4.xml · derivative · entry 1 BAXTER GREGORY T. · CIK 0001620138 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2025-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. Read SEC document |
| March 28, 2017 Filed Mar 29, 2017 12:00 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | GrantShare Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001144204-17-017153 · v462869_4.xml · derivative · entry 1 BAXTER GREGORY T. · CIK 0001620138 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2024-03-28 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third on March 23, 2018, as to one-third on March 23, 2019 and as to the remaining one-third on March 23, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.